Syndax Pharmaceuticals Inc

The stock failed its key support cluster near earlier lows and now trades below all major EMAs, signaling a breakdown rather than a pullback. The medium-term structure is bearish with further downside likely as supply overwhelms demand, and short-term price momentum confirms unfavorable timing. We are selling now into the continued decline, targeting participation in the accelerating down move.

• ↑Revuforj and Niktimvo generate ~$200M annually, validating commercial viability
• ↑Upcoming clinical data readouts could act as major growth catalysts
• ↓Profit margins are deeply negative and earnings yield remains below zero